Myriad's MyChoice Test Approved for Prostate Cancer in Japan

Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Myriad Genetics' MyChoice Test for prostate cancer patients as a companion diagnostic for Lynparza (olaparib). This approval expands the test's reimbursement under Japan's National Health Insurance, previously limited to breast and ovarian cancers, broadening access to critical genomic insights. The expansion is expected to benefit a portion of the over 100,000 men diagnosed with prostate cancer annually in Japan, particularly those with metastatic castration-resistant prostate cancer, by identifying patients who may benefit from PARP inhibitors.